Yesterday I looked at the biotech sector's outperformance of the headline-grabbing tech and small-cap sectors. Even better, I gave you a way to play it plus a way to juice what should be tidy profits.
But nonetheless, biotech stocks just aren't getting the same love as the highly touted "FANG" stocks and the like.
But that's okay with me – more money for the rest of us.
In fact, my "Best in Breed" (BIB) model excels at uncovering underappreciated outperformers. First, it looks for the strongest sectors. Then, it uncovers the highest fliers in those sectors – the cream of the crop.
Today, as promised, I have two biotech names that have not only outperformed this year, but should continue to outpace the large-cap tech media darlings as well as the on-fire small-cap sector.
Though both have outperformed in 2018, each one is subject to analyst skepticism that is not consistent with their technical strength. That's why I look for their rallies to continue throughout at least the next few months.
Without further ado, let's take a look at these beasts…
About the Author
Chris Johnson is a quant - he's obsessed with building and perfecting mathematical models that allow him to predict, with startling accuracy, the direction of the markets, entire sectors, and individual securities. For the last year, he's been researching and building a new system that lets him move swiftly in and out of the hottest stocks in the market for life-changing gains - entirely on his own terms. The results of his newly-minted Night Trader system are nothing short of amazing.
Chris also contributes to Money Morning as the Quant Analysis Specialist.